Eton Pharmaceuticals, Inc.
Financials
Valuation Metrics
Eton Pharmaceuticals, Inc.'s Market Cap is $1.45B. At end of 2025 it was $455M. Ranked #2182 of 3,118 in US market (top 70%), #855 of 1,474 on NASDAQ (top 58%), #160 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.45B | US#2,182/3,118 Sec#160/265 |
| Revenue | $106M | US#2,660/3,118 Sec#121/265 |
| Net Income | $13M | US#2,136/3,118 Sec#70/265 |
| Total Assets | $116M | US#3,041/3,118 Sec#258/265 |
| Net Assets | $47M | US#2,855/3,118 Sec#223/265 |
| Employees | 44 | US#2,708/3,118 Sec#211/265 |
| Value | ||
| P/E | 114.46x | US#2,128/3,118 Sec#68/265 |
| P/B | 31.18x | US#2,853/3,118 Sec#227/265 |
| P/S | 13.75x | US#2,789/3,118 Sec#132/265 |
| EV/EBITDA | 78.35x | US#2,405/3,118 Sec#76/265 |
| FCF Yield | 1.01% | US#2,164/3,118 Sec#79/265 |
| Profitability | ||
| ROE | 27.24% | US#349/3,118 Sec#20/265 |
| ROA | 10.96% | US#425/3,118 Sec#32/265 |
| Op. Margin | 15.44% | US#1,160/3,118 Sec#50/265 |
| Revenue Growth | 81.49% | US#124/3,118 Sec#36/265 |
| Financial Health | ||
| Debt Ratio | 148.59% | US#1,486/3,118 Sec#186/265 |
| Total Debt | $29M | US#2,687/3,118 Sec#177/265 |
| FCF | $15M | US#2,195/3,118 Sec#80/265 |
| Cash | $27M | US#2,778/3,118 Sec#247/265 |
| Current Ratio | 1.52x | US#1,628/3,118 Sec#236/265 |
| Net Debt/EBITDA | 0.12x | US#635/3,118 Sec#36/265 |
| Performance | ||
| 1Y Return | 182.12% | US#38/3,118 Sec#14/265 |
| 1M Return | -8.22% | US#1,627/3,118 Sec#98/265 |
| From 52W High | -23.44% | US#1,545/3,118 Sec#90/265 |
| 1Y MDD | -25.45% | US#974/3,118 Sec#42/265 |
| Trading | ||
| Volume | 550,139 shares | US#2,340/3,118 Sec#224/265 |
| Trading Value | $28M | US#1,978/3,118 Sec#147/265 |
| Per Share | ||
| EPS | $0.44 | US#1,895/3,118 Sec#61/265 |
| BPS | $1.63 | US#2,609/3,118 Sec#185/265 |
Company Info
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.